Ditchcarbon
  • Contact
  1. Organizations
  2. Daiichi Sankyo, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated a month ago

Daiichi Sankyo, Inc. Sustainability Profile

Company website

Daiichi Sankyo, Inc., a prominent player in the global pharmaceutical industry, is headquartered in the United States, with significant operations across Europe, Asia, and other regions. Founded in 2005 through the merger of Daiichi Pharmaceutical and Sankyo Company, Limited, the company has established itself as a leader in innovative medicines, particularly in oncology, cardiovascular, and vaccine development. Daiichi Sankyo is renowned for its unique approach to drug discovery and development, leveraging advanced technologies to create targeted therapies. Its core products, including the groundbreaking cancer treatment, have positioned the company as a key competitor in the pharmaceutical market. With a commitment to improving patient outcomes, Daiichi Sankyo continues to achieve notable milestones, solidifying its reputation as a trusted name in healthcare.

DitchCarbon Score

How does Daiichi Sankyo, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

74

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Daiichi Sankyo, Inc.'s score of 74 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.

84%

Let us know if this data was useful to you

Daiichi Sankyo, Inc.'s reported carbon emissions

Inherited from Daiichi Sankyo Company, Limited

Daiichi Sankyo, Inc., headquartered in the US, currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of Daiichi Sankyo Company, Limited, which may influence its climate commitments and initiatives. While there are no documented reduction targets or achievements from Daiichi Sankyo, Inc. itself, it is important to note that the parent company, Daiichi Sankyo Company, Limited, may have established climate initiatives that could impact its subsidiaries. The emissions data and climate strategies from Daiichi Sankyo Company, Limited are cascaded to Daiichi Sankyo, Inc. at a level 1 relationship. Daiichi Sankyo Company, Limited is involved in various climate initiatives, including the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), which may guide the climate commitments of its subsidiaries. However, specific targets or commitments from these initiatives have not been detailed for Daiichi Sankyo, Inc. In summary, while Daiichi Sankyo, Inc. does not currently report emissions data or specific reduction targets, it is part of a corporate family that may have broader climate commitments through its parent company.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20112012201320142015201620172018201920202021202220232024
Scope 1
182,519,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
290,715,000
000,000,000
000,000,000
000,000,000
-
000,000,000
000,000,000
000,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
5,704,000
-
-
-
-
-
-
-
-
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000

How Carbon Intensive is Daiichi Sankyo, Inc.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Daiichi Sankyo, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Daiichi Sankyo, Inc.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Daiichi Sankyo, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Daiichi Sankyo, Inc.'s Scope 3 Categories Breakdown

Daiichi Sankyo, Inc.'s Scope 3 emissions, which decreased by 6% last year and increased significantly since 2011, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 85% of Scope 3 emissions.

Top Scope 3 Categories

2024
Purchased Goods and Services
85%
Capital Goods
5%
Downstream Transportation & Distribution
4%
Upstream Transportation & Distribution
3%
Business Travel
1%
Fuel and Energy Related Activities
<1%
End-of-Life Treatment of Sold Products
<1%
Waste Generated in Operations
<1%
Employee Commuting
<1%
Downstream Leased Assets
<1%

Daiichi Sankyo, Inc.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Daiichi Sankyo, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Daiichi Sankyo, Inc.'s Emissions with Industry Peers

GeneScience Pharmaceuticals Co., Ltd.

CN
•
Pharmaceutical Preparation Manufacturing
Updated 16 days ago

Endo Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 10 days ago

Pfizer

US
•
Pharmaceutical Preparation Manufacturing
Updated about 2 hours ago

Zyla Life Sciences

US
•
Pharmaceutical Preparation Manufacturing
Updated 28 days ago

AMAG Pharmaceuticals, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 11 days ago

Zogenix, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 months ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251030.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy